Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Operations: 2010-2025

Historic Cash from Operations for Heron Therapeutics (HRTX) over the last 12 years, with Sep 2025 value amounting to $1.3 million.

  • Heron Therapeutics' Cash from Operations fell 60.52% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.2 million, marking a year-over-year decrease of 263.96%. This contributed to the annual value of -$22.5 million for FY2024, which is 61.68% up from last year.
  • Heron Therapeutics' Cash from Operations amounted to $1.3 million in Q3 2025, which was up 112.25% from -$10.9 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Cash from Operations high stood at $3.4 million for Q3 2024, and its period low was -$63.0 million during Q2 2021.
  • For the 3-year period, Heron Therapeutics' Cash from Operations averaged around -$9.1 million, with its median value being -$9.2 million (2023).
  • Within the past 5 years, the most significant YoY rise in Heron Therapeutics' Cash from Operations was 136.73% (2024), while the steepest drop was 579.84% (2024).
  • Heron Therapeutics' Cash from Operations (Quarterly) stood at -$45.3 million in 2021, then grew by 17.07% to -$37.5 million in 2022, then soared by 106.54% to $2.5 million in 2023, then plummeted by 579.84% to -$11.8 million in 2024, then slumped by 60.52% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, -$10.9 million for Q2 2025, and -$8.9 million during Q1 2025.